[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Both the soft tissue sarcomas and the neuroendocrine tumors are rare diseases. Therefore the recruiting of these patients was more difficult than other cancer species, and the development of the new therapy for these diseases did not readily advance. However, the identification of driver molecules for each sub-type enabled us to the development of the molecular targeted drugs. As for the GIST, several TKIs are used, but in late years it is found that susceptibility of TKIs varies according to difference in second mutation. In this chapter, the molecular target drug for the soft tissue sarcoma and the neuroendocrine tumor is reviewed.
Shunsuke
S
Kato
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D000069448:Denosumab; D055808:Drug Discovery; D000068338:Everolimus; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D007191:Indazoles; D007211:Indoles / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000235:genetics*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy* / Q000235:genetics*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib; D013449:Sulfonamides / Q000627:therapeutic use; D000077210:Sunitinib
D061067:Antibodies, Monoclonal, Humanized; D001549:Benzamides; D007191:Indazoles; D007211:Indoles; D010671:Phenylurea Compounds; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D009536:Niacinamide; D000069448:Denosumab; C516667:pazopanib; D000068877:Imatinib Mesylate; D000068338:Everolimus; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib; D020123:Sirolimus